Old Web
English
Sign In
Acemap
>
authorDetail
>
Karsten Witt
Karsten Witt
OSI Pharmaceuticals
Erlotinib
Medicine
Pharmacokinetics
Pharmacology
Lung cancer
3
Papers
83
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects
2014
Cancer Chemotherapy and Pharmacology
Marta Hamilton
Julie L. Wolf
Daniel W. Drolet
Scott Fettner
Ashok Rakhit
Karsten Witt
Bert L. Lum
Show All
Source
Cite
Save
Citations (27)
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function
2012
Cancer Chemotherapy and Pharmacology
Cindy L. O’Bryant
Paul Haluska
Lee S. Rosen
Ramesh K. Ramanathan
Balaji Venugopal
Stephen Leong
Ramesh Boinpally
Amy Franke
Karsten Witt
Jeffry Evans
Chandra P. Belani
S. Gail Eckhardt
Suresh Ramalingam
Show All
Source
Cite
Save
Citations (19)
Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
2011
British Journal of Cancer
Alain C. Mita
Kyriakos P. Papadopoulos
M.J.A. de Jonge
Garry Schwartz
Jaap Verweij
Monica M. Mita
A. Ricart
Q S-C Chu
Anthony W. Tolcher
Leslie Wood
S McCarthy
M. Hamilton
Kenneth K. Iwata
Bret Wacker
Karsten Witt
Eric K. Rowinsky
Show All
Source
Cite
Save
Citations (37)
1